Dr. Alain Wagner received a PhD in organic chemistry from Université Louis Pasteur (1991), followed by a post-doctoral fellowship with Prof. Peter Schultz at Affymax Research Institute (1991-1993, Palo Alto, USA). He joined CNRS in 1994 to develop projects dealing with combinatorial approaches in drug discovery. Promoted research director in 2001, Alain Wagner took a sabbatical to found Novalix Pharma (2002-2007). He later participated actively in the creation of eNovalys (2009) a pioneering company that stake on the digital technology exploiting raw experimental data as a source of innovation. On returning to the CNRS (2008) he took the lead of the BioFunctional Chemistry Lab (www.biofunctional.eu) to investigate xenobiotic synthetic reactivity for interfering with living organisms. Alain has recently co-founded Syndivia SAS, which provides advanced technologies for drug bio-conjugation / drug release (2014). Dr Wagner published more than 150 articles and is an inventor of 22 patents. He is currently involved in the creation of MicroOmiX Technology a company developing advanced single cell secretomic analytics.